DSGN Phase 1 readout: a negative outcome, -25.5%

On May 18, 2026, Design Therapeutics, Inc. reached its Phase 1 readout. The result was a negative outcome, and the stock moved -25.5% in the window around the event. It had already run +9.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.